Genetic susceptibility to adverse drug reactions

Trends in Pharmacological Sciences

Volumn 22, Issue 6, 2001, Pages 298-305

  Pirmohamed, Munir ^a   Park, B Kevin ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMONAFIDE; ANTIARRHYTHMIC AGENT; ANTILEUKEMIC AGENT; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYTOCHROME P450; DAPSONE; DIAZEPAM; FLUOROURACIL; HYDRALAZINE; ION CHANNEL; IRINOTECAN; ISONIAZID; MEPHENYTOIN; MERCAPTOPURINE; NEUROLEPTIC AGENT; NITRITE; NITROFURANTOIN; OPIATE; PERHEXILINE; PHENFORMIN; PHENYTOIN; PRIMAQUINE; PROCAINAMIDE; SULFONAMIDE; SUXAMETHONIUM; TOLBUTAMIDE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; WARFARIN;

CLINICAL ARTICLE; DISEASE SEVERITY; DNA POLYMORPHISM; DOSE RESPONSE; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG TARGETING; ENZYME DEFECT; ENZYME STRUCTURE; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOME; GENOTYPE; HEREDITY; HUMAN; IMMUNE RESPONSE GENE; MEMBRANE TRANSPORT; MORBIDITY; MORTALITY; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; GENETIC SCREENING; HLA ANTIGENS; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 0035369825     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-6147(00)01717-X     Document Type: Review

References (87)

1. Incidence of adverse drug reactions in hospitalized patients - A meta-analysis of prospective studies
2. Adverse drug reactions in hospitalized patients: A critique of a meta-analysis
3. Drug-related hospital admissions
4. Incidence of adverse drug events and potential adverse drug events - Implications for prevention
5. The costs of adverse drug events in hospitalized patients
6. New active substances authorized in the United Kingdom between 1972 and 1994
7. Pharmacogenetics and pharmacogenomics: Why is this relevant to the clinical geneticist?
8. Getting the right drug into the right patient
9. Adverse drug reactions: Definitions, diagnosis, and management
10. Mechanisms of adverse drug reactions
11. The role of drug disposition in drug hypersensitivity: A chemical, molecular and clinical perspective
12. Adverse drug reactions
13. Pharmacogenetics and adverse drug reactions
14. A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: Association with tardive dyskinesia in schizophrenia
15. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
16. The genetic polymorphism of debrisoquine/sparteine metabolism - Clinical aspects
17. The role of cytochrome P450 enzymes in hepatic and extrahepatic human drug toxicity
18. Association of CYP3A4 genotype with treatment-related leukemia
19. Pharmacogenetics
20. Polymorphic human cytochrome P450 enzymes: An opportunity for individualized drug treatment
21. Toxicogenetics in drug development
22. Extension of a pilot study: Impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness
23. Prevention of stroke in patients with nonvalvular atrial fibrillation
24. Frequency of major complications of aspirin, warfarin, and intravenous heparin for secondary stroke prevention - A population-based study
25. Hydroxylation of warfarin by human cDNA-expressed cytochrome-P-450 - A role for P-4502C9 in the etiology of (s)-warfarin drug-interactions
26. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy
27. Allelic variants of human cytochrome P450 2C9: Baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms
28. Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: Catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes
29. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment
30. Cytochrome P450 polymorphisms are associated with reduced warfarin dose
31. Human P450 metabolism of warfarin
32. Warfarin usage: Can safety be improved?
33. Multicentre randomised study of computerised anticoagulant dosage
34. Oral anticoagulation self-management and management by a specialist anticoagulation clinic: A randomised cross-over comparison
35. Idiosyncratic drug reactions: A mechanistic evaluation of risk factors
36. N acetyltransferase
37. Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia
38. Pharmacogenetics: A tool for individualising antineoplastic therapy
39. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: A pharmacogenetic analysis
40. Association analysis of drug metabolizing enzyme gene polymorphisms in HIV-positive patients with co-trimoxazole hypersensitivity
41. Mechanisms of idiosyncratic hypersensitivity reactions to antiepileptic drugs
42. Glutathione S-transferase μ genotype (GSTM1*O) in Alzheimer's patients with tacrine transaminitis
43. No association between tacrine transaminitis and the glutathione transferase theta genotype in patients with Alzheimer's disease
44. The purine path to chemotherapy
45. Pharmacogenetics of cancer therapy: Getting personal
46. Molecular diagnosis of thiopurine S-methyltransferase deficiency: Genetic basis for azathioprine and mercaptopurine intolerance
47. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia
48. Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient
49. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia
50. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus
51. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia
52. High incidence of secondary brain tumours after radiotherapy and antimetabolites
53. Human erythrocyte thiopurine methyltransferase: Radiochemical microassay and biochemical properties
54. Polymorphisms in UDP glucuronosyltransferase genes: Functional consequences and clinical relevance
55. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes
56. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism
57. P-glycoprotein in the blood-brain-barrier of mice influences the brain penetration and pharmacological activity of many drugs
58. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo
59. Idiosyncratic drug reactions
60. Glucose-6-phosphate dehydrogenase deficiency
61. A transcription-activating polymorphism in the ACHE promoter associated with acute sensitivity to anti-acetylcholinesterases
62. Association between β2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitization in moderately severe stable asthmatics
63. Pharmacogenomics of psychiatric disorders
64. Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia
65. Ryanodine receptor mutations in malignant hyperthermia and central core disease
66. + channels
67. Potassium channels: Molecular defects, diseases, and therapeutic opportunities
68. MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia
69. A common polymorphism associated with antibiotic-induced cardiac arrhythmia
70. Idiosyncratic drug reactions: The reactive metabolite syndromes
71. Single nucleotide polymorphisms as tools in human genetics
72. Complete sequence and gene map of a human major histocompatibility complex
73. An allelic polymorphism within the human tumor-necrosis-factor-α promoter region is strongly associated with HLA-A1, HLA-B8, and HLA-DR3 alleles
74. Idiosyncratic drug reactions: Metabolic bioactivation as a pathogenic mechanism
75. Investigation of mechanisms in toxic epidermal necrolysis induced by carbamazepine
76. Genetic predisposition to phenytoin-induced birth defects
77. Concordance of primary generalised epilepsy and carbamazepine hypersensitivity in monozygotic twins
78. Anticonvulsant hypersensitivity syndrome: In vitro risk assessment
79. Carbamazepine hypersensitivity: Assessment of clinical and in vitro chemical cross-reactivity with phenytoin and oxcarbazepine
80. Characterization of the microsomal epoxide hydrolase gene in patients with anticonvulsant adverse drug reactions
81. Genetic analysis of microsomal epoxide hydrolase in patients with carbamazepine hypersensitivity
82. TNF-α promoter region gene polymorphisms in carbamazepine-hypersensitive patients
83. Interpretation of results from genetic studies of multifactorial diseases
84. Pharmacogenetics and the practice of medicine
85. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms
86. Pharmacogenetics in the new patterns of healthcare delivery
87. Testing drug response in the presence of genetic information: Sampling issues for clinical trials